PDCD1 and neoplasm: These mechanisms could potentially enhance the efficacy of anti-PD1/PD-L1 blockade and we chose to evaluate the efficacy of our anti–PD-L1-mIFN-α in a syngeneic mouse tumor model LL/2 that is nonresponsive to anti-PD-L1 treatment.